Charles River Laboratories International Inc. (NYSE:CRL) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $87.98 and last traded at $87.98, with a volume of 143,927 shares. The stock had previously closed at $86.35.

CRL has been the topic of several research analyst reports. Gabelli initiated coverage on shares of Charles River Laboratories International in a research note on Tuesday, April 26th. They issued a “buy” rating and a $96.00 price objective on the stock. Zacks Investment Research downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, May 5th. Barclays PLC raised their price objective on shares of Charles River Laboratories International from $60.00 to $65.00 and gave the stock an “underweight” rating in a research note on Friday, May 20th. KeyCorp reaffirmed a “hold” rating and issued a $77.00 target price on shares of Charles River Laboratories International in a research report on Sunday, May 22nd. Finally, Credit Suisse Group AG assumed coverage on Charles River Laboratories International in a research report on Monday, June 20th. They issued a “neutral” rating and a $84.00 target price for the company. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $83.27.

The firm has a market capitalization of $4.11 billion and a price-to-earnings ratio of 26.81. The stock’s 50-day moving average price is $84.08 and its 200-day moving average price is $79.24.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, May 4th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.08. During the same period in the prior year, the company earned $0.79 earnings per share. The firm earned $354.90 million during the quarter, compared to analyst estimates of $354.92 million. The business’s quarterly revenue was up 10.8% compared to the same quarter last year. Equities analysts predict that Charles River Laboratories International Inc. will post $4.39 EPS for the current fiscal year.

In other news, CAO John J. Crowley sold 1,913 shares of the stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $85.00, for a total transaction of $162,605.00. Following the sale, the chief accounting officer now directly owns 6,883 shares of the company’s stock, valued at approximately $585,055. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Richard F. Wallman sold 11,990 shares of the stock in a transaction on Tuesday, May 10th. The stock was sold at an average price of $84.00, for a total value of $1,007,160.00. Following the sale, the director now directly owns 27,420 shares in the company, valued at $2,303,280. The disclosure for this sale can be found here.

Several hedge funds recently added to or reduced their stakes in CRL. Vanguard Group Inc. raised its stake in Charles River Laboratories International by 2.4% in the fourth quarter. Vanguard Group Inc. now owns 4,182,744 shares of the company’s stock valued at $336,251,000 after buying an additional 97,314 shares during the period. Van Berkom & Associates Inc. raised its stake in Charles River Laboratories International by 5.0% in the fourth quarter. Van Berkom & Associates Inc. now owns 719,334 shares of the company’s stock valued at $57,827,000 after buying an additional 34,470 shares during the period. Victory Capital Management Inc. raised its stake in Charles River Laboratories International by 7.0% in the fourth quarter. Victory Capital Management Inc. now owns 490,834 shares of the company’s stock valued at $39,458,000 after buying an additional 32,031 shares during the period. Hodges Capital Management Inc. raised its stake in Charles River Laboratories International by 0.4% in the fourth quarter. Hodges Capital Management Inc. now owns 390,676 shares of the company’s stock valued at $31,406,000 after buying an additional 1,706 shares during the period. Finally, Morgan Stanley raised its stake in Charles River Laboratories International by 23.3% in the fourth quarter. Morgan Stanley now owns 293,248 shares of the company’s stock valued at $23,573,000 after buying an additional 55,393 shares during the period.

Charles River Laboratories International, Inc is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.